Home > Compound List > Product Information
Trazodone hydrochloride_Molecular_structure_CAS_25332-39-2)
Click picture or here to close

Trazodone hydrochloride

Catalog No. S2582 Name Selleck Chemicals
CAS Number 25332-39-2 Website http://www.selleckchem.com
M. F. C19H23Cl2N5O Telephone (877) 796-6397
M. W. 408.32482 Fax (832) 582-8590
Purity Email sales@selleckchem.com
Storage -20°C Chembase ID: 73240

SYNONYMS

IUPAC name
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride
IUPAC Traditional name
trazodone hydrochloride
Synonyms
Desyrel

DATABASE IDS

CAS Number 25332-39-2

PROPERTIES

Target Serotonin receptor
Salt Data hydrochloride
Storage Condition -20°C

DETAILS

Description (English)
Research Area: Cancer
Biological Activity:
Trazodone hydrochloride (Desyrel) is a hydrochloride salt of trazodone that is a serotonin antagonist and reuptake inhibitor with a Kd of 0.16 μM. Trazodone hydrochloride is a triazolopyridine antidepressant drug. Trazodone is a phenylpiperazine compound. [1][2] Trazodone also has anxiolytic, and hypnotic effects. Trazodone is a psychoactive compound with sedative and anti-depressant properties. Trazodone may also be used for relief of an anxiety disorder (e.g., sleeplessness, tension) and chronic pain. Trazodone behaves as an antagonist at all of the following receptors except 5-HT1A where it acts as a partial agonist similarly to buspirone and tandospirone but with greater intrinsic activity in comparison: 5-HT1A receptor (Kd = 78 nM), 5-HT2A receptor (Ki = 13 nM), 5-HT2C receptor (Ki = 192 nM), α1-adrenergic receptor (Kd = 39 nM), α2-adrenergic receptor (Kd = 405 nM), H1 receptor (Kd = 725 nM). Trazodone acts predominantly as a 5-HT2A receptor antagonist to mediate its therapeutic benefits against anxiety and depression. [3][4] References on Trazodone HCl (Desyrel)[1] http://en.wikipedia.org/wiki/Trazodone, , [2] Psychopharmacology (Berl)., 1992, 109(1-2):2-11[3] J Pharmacol Exp Ther., 1984 Jul, 230(1):94-102[4] Eur J Pharmacol., 1986 Dec 16, 132(2-3):115-21

REFERENCES

  • Wander TJ et al. Eur J Pharmacol. 1986 Dec 16;132(2-3):115-21.